Skip to main content
SpringerLink
Log in

Guillain-Barré Syndrome

  • Chapter
  • First Online:
Emergency Neurology

Abstract

Acute weakness is a neurologic emergency, and one of the most frequent causes is Guillain-Barré syndrome (GBS). GBS is a syndrome encompassing multiple different forms of acute polyradiculoneuropathies. This chapter reviews the diagnosis and management of this classic neuromuscular condition by focusing on an understanding of the underlying disease mechanisms. The epidemiology, clinical features/variants, and differential diagnosis of GBS will be summarized, as will differentiation of acute inflammatory demyelinating polyradiculoneuropathy (AIDP) (the most common form of GBS) from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The pathogenesis behind the disease will be discussed, followed by an evidence-based review of approved immunomodulatory therapy and treatment options still in clinical trials. Associated systemic complications are covered, as well as prognosis of patients presenting with various forms of Guillain-Barré syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Dumenil L. Paralysie peripherique du movement et du sentiment portant sur les cuatre members. Atrophie des rameaux nerveux des parties paralysies. Gaz Hebd Med. 1864;1:203–6.

    Google Scholar 

  2. Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculo-névrite avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire. Remarques sur les caractères cliniques et graphiques des réflexes tendineux. Ann Med Interne (Paris). 1999;150(1):1462–70.

    Google Scholar 

  3. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36:123–33.

    Article  PubMed  Google Scholar 

  4. Hughes RAC, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005;366(9497):1653–66.

    Article  CAS  PubMed  Google Scholar 

  5. Webb AJS, Brain SAE, Wood R, Rinaldi S, Turner MR. Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. J Neurol Neurosurg Psychiatry. 2015;86(11):1196–201.

    Article  PubMed  Google Scholar 

  6. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, et al. Guillain-barré syndrome in Northern China relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118(3):597–605.

    Article  PubMed  Google Scholar 

  7. McKhann GM, Cornblath DR, Ho T, Griffin JW, Li CY, Bai AY, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet. 1991;338(8767):593–7.

    Article  CAS  PubMed  Google Scholar 

  8. Winer JB, Hughes RAC, Anderson MJ, Jones DM, Kangro H, Watkinsh RPF. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry. 1988;51(5):613–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Koga M, Yuki N, Hirata K. Antecedent symptoms in Guillain-Barré syndrome: an important indicator for clinical and serological subgroups. Acta Neurol Scand. 2001;103(5):278–87.

    Article  CAS  PubMed  Google Scholar 

  10. Hadden RDM, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology. 2001;56(6):758–65.

    Article  CAS  PubMed  Google Scholar 

  11. Hao Y, Wang W, Jacobs BC, Qiao B, Chen M, Liu D, et al. Antecedent infections in Guillain-Barré syndrome: a single-center, prospective study. Ann Clin Transl Neurol. 2019;6(12):2510–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531–9.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Parra B, Lizarazo J, Jiménez-Arango JA, Zea-Vera AF, González-Manrique G, Vargas J, et al. Guillain-Barré syndrome associated with Zika virus infection in Colombia. N Engl J Med. 2016;375(16):1513–23.

    Article  PubMed  Google Scholar 

  14. Paybast S, Gorji R, Mavandadi S. Guillain-Barré syndrome as a neurological complication of novel COVID-19 infection: a case report and review of the literature. Neurologist. 2020;25(4):101–3.

    Article  PubMed  Google Scholar 

  15. Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: a case report. J Clin Neurosci. 2020;76:233–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Rodríguez Y, Novelli L, Rojas M, De Santis M, Acosta-Ampudia Y, Monsalve DM, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun. 2020;114:102506.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Farzi MA, Ayromlou H, Jahanbakhsh N, Bavil PH, Janzadeh A, Shayan FK. Guillain-Barré syndrome in a patient infected with SARS-CoV-2, a case report. J Neuroimmunol. 2020;346:577294.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020;95(5):601–5.

    Google Scholar 

  19. Toro G, Vergara I, Romén G. Neuroparalytic accidents of Antirabies vaccination with suckling mouse brain vaccine: clinical and pathologic study of 21 cases. Arch Neurol. 1977;34(11):694–700.

    Article  CAS  PubMed  Google Scholar 

  20. Appelbaum E, Nelson J. Neurological complications following antirabies vaccination. J Am Med Assoc. 1953;151(3):188–91.

    CAS  PubMed  Google Scholar 

  21. Hemachudha T, Griffin DE, Chen WW, Johnson RT. Immunologic studies of rabies vaccination-induced Guillain-Barré syndrome. Neurology. 1988;38(3):375–8.

    Article  CAS  PubMed  Google Scholar 

  22. Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome. Drug Safety. 2009;32:309–23.

    Article  CAS  PubMed  Google Scholar 

  23. Schonberger LB, Bregman DJ, Sullivan-bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, et al. Guillain-Barre syndrome following vaccination in the national influenza immunization program, United States, 1976–1977. Am J Epidemiol. 1979;110(2):105–23.

    Article  CAS  PubMed  Google Scholar 

  24. Safranek TJ, Lawrence DN, Kuriand LT, Culver DH, Wiederholt WC, Hayner NS, et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976–1977: Results of a two-state study. Am J Epidemiol. 1991;133(9):940–51.

    Article  CAS  PubMed  Google Scholar 

  25. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, et al. The Guillain-Barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med. 1998;339(25):1797–802.

    Article  CAS  PubMed  Google Scholar 

  26. Lehmann HC, Hartung HP, Kieseier BC, Hughes RAC. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis. 2010;10:643–51.

    Article  PubMed  Google Scholar 

  27. Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barré syndrome with influenza vaccine and influenzalike illness using the United Kingdom general practice research database. Am J Epidemiol. 2009;169(3):382–8.

    Article  PubMed  Google Scholar 

  28. Hughes R, Rees J, Smeeton N, Winer J. Vaccines and Guillain-Barre syndrome. BMJ. 1996;312:1475.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Souayah N, Nasar A, Suri MFK, Qureshi AI. Guillain-Barre syndrome after vaccination in United States. A report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine. 2007;25(29):5253–5.

    Article  PubMed  Google Scholar 

  30. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939–50.

    Article  PubMed  Google Scholar 

  31. Pritchard J, Mukherjee R, Hughes RAC. Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation [7]. J Neurol Neurosurg Psychiatry. 2002;73:348–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Chen Y, Zhang J, Chu X, Xu Y, Ma F. Vaccines and the risk of Guillain-Barré syndrome. Eur J Epidemiol. 2020;35(4):363–70.

    Article  PubMed  Google Scholar 

  33. Baxter R, Lewis N, Bakshi N, Vellozzi C, Klein NP. Recurrent Guillain-Barré syndrome following vaccination. Clin Infect Dis. 2012;54(6):800–4.

    Article  PubMed  Google Scholar 

  34. Rudant J, Dupont A, Mikaeloff Y, Bolgert F, Coste J, Weill A. Surgery and risk of Guillain-Barré syndrome. Neurology. 2018;91(13):e1220–7.

    Article  PubMed  Google Scholar 

  35. Arnason BG, Asbury AK. Idiopathic polyneuritis after surgery. Arch Neurol. 1968;18(5):500–7.

    Article  CAS  PubMed  Google Scholar 

  36. Myers TR, McCarthy NL, Panagiotakopoulos L, Omer SB. Estimation of the incidence of Guillain-Barré syndrome during pregnancy in the United States. Open Forum Infect Dis. 2019;6(3):1–3.

    Google Scholar 

  37. Jia H, Tian Y, Wu Y-M, Li B. Two cases of Guillain-Barré syndrome after cerebral hemorrhage or head trauma. Neuroimmunol Neuroinflammation. 2017;4(4):61–4.

    Article  Google Scholar 

  38. Chi L-J, Wang H-B, Zhang Y, Wang W-Z. Abnormality of circulating CD4+CD25+ regulatory T cell in patients with Guillain-Barré syndrome. J Neuroimmunol. 2007;192(1–2):206–14.

    Article  CAS  PubMed  Google Scholar 

  39. Maddur MS, Rabin M, Hegde P, Bolgert F, Guy M, Vallat JM, et al. Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain–Barré syndrome patients. Immunol Res. 2014;60(2–3):320–9.

    Article  CAS  PubMed  Google Scholar 

  40. Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol. 2001;49(6):712–20.

    Article  CAS  PubMed  Google Scholar 

  41. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci U S A. 2004;101(31):11404–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry. 2001;70(1):50–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Mori M, Kuwabara S, Miyake M, Dezawa M, Adachi-Usami E, Kuroki H, et al. Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain-Barre syndrome. Neurology. 1999;52(6):1282–4.

    Article  CAS  PubMed  Google Scholar 

  44. Koga M, Yuki N, Tai T, Hirata K. Miller Fisher syndrome and Haemophilus influenzae infection. Neurology. 2001;57(4):686–91.

    Article  CAS  PubMed  Google Scholar 

  45. Susuki K, Odaka M, Mori M, Hirata K, Yuki N. Acute motor axonal neuropathy after Mycoplasma infection: evidence of molecular mimicry. Neurology. 2004;62(6):949–56.

    Article  CAS  PubMed  Google Scholar 

  46. Ang CW, Tio-Gillen AP, Groen J, Herbrink P, Jacobs BC, Van Koningsveld R, et al. Cross-reactive anti-galactocerebroside antibodies and Mycoplasma pneumoniae infections in Guillain-Barré syndrome. J Neuroimmunol. 2002;130(1–2):179–83.

    Article  CAS  PubMed  Google Scholar 

  47. Kusunoki S, Kaida KI. Antibodies against ganglioside complexes in Guillain-Barré syndrome and related disorders. J Neurochem. 2011;116:828–32.

    Article  CAS  PubMed  Google Scholar 

  48. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis: Its role in pathogenesis. Medicine (United States). 1969;48(3):173–215.

    CAS  Google Scholar 

  49. Prineas JW. Pathology of the Guillain-Barré syndrome. Ann Neurol. 1981;9(1 S):6–19.

    Google Scholar 

  50. Hafer-Macko C, Hsieh ST, Yan Li C, Ho TW, Sheikh K, Cornblath DR, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol. 1996;40(4):635–44.

    Article  CAS  PubMed  Google Scholar 

  51. Griffin JW, Li CY, Macko C, Ho TW, Hsieh ST, Xue P, et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol. 1996;25(1):33–51.

    Article  CAS  PubMed  Google Scholar 

  52. Kuwabara S, Bostock H, Ogawara K, Sung JY, Kanai K, Mori M, et al. The refractory period of transmission is impaired in axonal Guillain-Barré syndrome. Muscle Nerve. 2003;28(6):683–89.

    Google Scholar 

  53. Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S. Differences in patterns of progression in demyelinating and axonal Guillain-Barré syndromes. Neurology. 2003;61(4):471–4.

    Google Scholar 

  54. Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, Koopman WF, et al. An acute axonal form of Guillain-Barrée polyneuropathy. Brain. 1986;109(6):1115–26.

    Google Scholar 

  55. Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol. 1996;39(1):17–26.

    Google Scholar 

  56. Yu RK, Tsai YT, Ariga T, Yanagisawa M. Structures, biosynthesis, and functions of gangliosides-an overview. J Oleo Sci. 2011;60:537–44.

    Google Scholar 

  57. Anderson RGW. The caveolae membrane system. Ann Rev Biochem. 1998;67:199–225.

    Google Scholar 

  58. Illa I, Ortiz N, Gallard E, Juarez C, Grau JM, Dalakas MC. Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol. 1995;38(2):218–24.

    Google Scholar 

  59. Dasgupta S, Li D, Yu RK. Lack of apparent neurological abnormalities in rabbits sensitized by gangliosides. Neurochem Res. 2004;29(11 SPEC. ISS.):2147–52.

    Google Scholar 

  60. Lehmann HC, Lopez PHH, Zhang G, Ngyuen T, Zhang J, Kieseier BC, et al. Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model. J Neurosci. 2007;27(1):27–34.

    Google Scholar 

  61. Nishimoto Y, Odaka M, Hirata K, Yuki N. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol. 2004;148(1–2):200–5.

    Google Scholar 

  62. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res. 1997;745(1–2):32–36.

    Google Scholar 

  63. Ito H, Hatanaka Y, Fukami Y, Harada Y, Kobayashi R, Okada H, et al. Anti-ganglioside complex antibody profiles in a recurrent complicated case of GQ1b-seronegative miller fisher syndrome and Bickerstaff brainstem encephalitis: A case report. BMC Neurol. 2018;18(1):1–4.

    Google Scholar 

  64. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27(1 S):21–4.

    Google Scholar 

  65. Löffel NB, Rossi LN, Mumenthaler M, Lütschg J, Ludin HP. The Landry-Guillain-Barré syndrome. Complications, prognosis and natural history in 123 cases. J Neurol Sci. 1977;33(1–2):71–9.

    Google Scholar 

  66. Oh SJ, Kurokawa K, De Almeida DF, Ryan HF, Claussen GC. Subacute inflammatory demyelinating polyneuropathy. Neurology. 2003;61(11):1507–12.

    Google Scholar 

  67. Rodriguez-Casero MV, Shield LK, Kornberg AJ. Subacute inflammatory demyelinating polyneuropathy in children. Neurology. 2005;64(10):1786–8.

    Google Scholar 

  68. Walgaard C, Lingsma HF, Ruts L, Drenthen J, Van Koningsveld R, Garssen MJP, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010;67(6):781–7.

    Google Scholar 

  69. Rees JH, Thompson RD, Smeeton NC, Hughes RAC. Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry. 1998;64(1):74–7.

    Google Scholar 

  70. Hughes RAC, Hadden RDM, Rees JH, Swan A V., Beghi E, Bogliun G, et al. The Italian Guillain-Barre study group. The prognosis and main prognostic indicators of Guillain-Barre syndrome: A multicentre prospective study of 297 patients (multiple letters) [1]. Brain. 1998;121:2053–61.

    Google Scholar 

  71. Dubey D, Kapotic M, Freeman M, Sawhney A, Rojas JC, Warnack W, et al. Factors contributing to delay in diagnosis of Guillain-Barré syndrome and impact on clinical outcome. Muscle Nerve. 2016;53(3):384–7.

    Google Scholar 

  72. Pentland B, Donald SM. Pain in the Guillain-Barré syndrome: a clinical review. Pain. 1994;59(2):159–64.

    Google Scholar 

  73. Ruts L, Van Doorn PA, Lombardi R, Haasdijk ED, Penza P, Tulen JHM, et al. Unmyelinated and myelinated skin nerve damage in Guillain-Barré syndrome: Correlation with pain and recovery. Pain. 2012;153(2):399–409.

    Google Scholar 

  74. Ruts L, Drenthen J, Jongen JLM, Hop WCJ, Visser GH, Jacobs BC, et al. Pain in Guillain-Barré syndrome: a long-term follow-up study. Neurology. 2010;75(16):1439–47.

    Google Scholar 

  75. Pan CL, Tseng TJ, Lin YH, Chiang MC, Lin WM, Hsieh ST. Cutaneous innervation in Guillain-Barré syndrome: pathology and clinical correlations. Brain. 2003;126(2):386–97.

    Google Scholar 

  76. Chakraborty T, Kramer CL, Wijdicks EFM, Rabinstein AA. Dysautonomia in Guillain-Barré Syndrome: s. Neurocrit Care. 2020;32(1):113–20.

    Google Scholar 

  77. Zochodne DW. Autonomic involvement in Guillain–Barre syndrome: a review. Muscle Nerve. 1994;17(10):289–99.

    Google Scholar 

  78. Feasby TE, Hahn AF, Brown WF, Bolton CF, Gilbert JJ, Koopman WJ. Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms? J Neurol Sci. 1993;116(2):185–92.

    Google Scholar 

  79. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255(2):57–65.

    Google Scholar 

  80. Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001;56(8):1104–6.

    Google Scholar 

  81. Fross RD, Daube JR. Neuropathy in the miller fisher syndrome: clinical and electrophysiologic findings. Neurology. 1987;37(9):1493–8.

    Google Scholar 

  82. Bickerstaff ER. Brain stem encephalitis (Bickerstaff’s encephalitis). 1978. 605–9 p.

    Google Scholar 

  83. Al-din AN, Anderson M, Bickerstaff ER, Harvey I. Brainstem encephalitis and the syndrome of miller fisher a clinical study. Brain. 1982;105(3):481–95.

    Google Scholar 

  84. Ropper AH. Unusual clinical variants and signs in Guillain-Barré Syndrome. Arch Neurol. 1986;43(11):1150–2.

    Google Scholar 

  85. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol. 2007;64(10):1519–23.

    Google Scholar 

  86. Quintas S, López Ruiz R, Ramos C, Vivancos J, Zapata-Wainberg G. Pharyngeal-cervical-brachial variant of Guillain-Barré syndrome with predominant bulbar palsy and anti-GM3 IgG antibodies. Neurol Sci. 2018;39:1291–2.

    Google Scholar 

  87. Morris AMS, Elliott EJ, D’Souza RM, Antony J, Kennett M, Longbottom H. Acute flaccid paralysis in Australian children. J Paediatr Child Health. 2003;39(1):22–6.

    Google Scholar 

  88. Korinthenberg R, Trollmann R, Felderhoff-Müser U, Bernert G, Hackenberg A, Hufnagel M, et al. Diagnosis and treatment of Guillain-Barré Syndrome in childhood and adolescence: an evidence- and consensus-based guideline. Europ J Paediatr Neurol. 2020;25:5–16.

    Google Scholar 

  89. Bradshaw DY, Jones HR. Guillain-Barré syndrome in children: clinical course, electrodiagnosis, and prognosis. Muscle Nerve. 1992;15(4):500–6.

    Google Scholar 

  90. Ryan MM. Guillain-Barré syndrome in childhood. J Paediatri Child Health. 2005;41:237–41.

    Google Scholar 

  91. Delanoe C, Sebire G, Landrieu P, Huault G, Metral S. Acute inflammatory demyelinating polyradiculopathy in children: clinical and electrodiagnostic studies. Ann Neurol. 1998;44(3):350–6.

    Google Scholar 

  92. Jones HR. Childhood Guillain-Barre syndrome: clinical presentation, diagnosis, and therapy. J Child Neurol. 1996;11:4–12.

    Google Scholar 

  93. Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, Van Doorn PA. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst. 2009;14(4):310–5.

    Google Scholar 

  94. Van Den Berg B, Bunschoten C, Van Doorn PA, Jacobs BC. Mortality in Guillain-Barré syndrome. Neurology. 2013;80(18):1650–4.

    Google Scholar 

  95. Walgaard C, Lingsma HF, Ruts L, Van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology. 2011;76(11):968–75.

    Google Scholar 

  96. Visser LH, Schmitz PIM, Meulstee J, Van Doorn PA, Van Der Meché FGA. Prognostic factors of Guillain-Barre syndrome after intravenous immunoglobulin or plasma exchange. Neurology. 1999;53(3):598–604.

    Google Scholar 

  97. Cornblath DR, Mellits ED, Griffin JW, McKhann GM, Albers JW, Miller RG, et al. Motor conduction studies in Guillain-Barré syndrome: Description and prognostic value. Ann Neurol. 1988;23(4):354–9.

    Google Scholar 

  98. Solomon T, Willison H. Infectious causes of acute flaccid paralysis. Curr Opin Infect Dis. 2003;16:375–81.

    Google Scholar 

  99. Gwathmey KG. Sensory neuronopathies. Muscle Nerve. 2016;53:8–19.

    Google Scholar 

  100. Logina I, Donaghy M. Diphtheritic polyneuropathy: a clinical study and comparison with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 1999;67:433–8.

    Google Scholar 

  101. Grattan-Smith PJ, Morris JG, Johnston HM, Yiannikas C, Malik R, Russell R, et al. Clinical and neurophysiological features of tick paralysis. Brain. 1997;120(11):1975–87.

    Google Scholar 

  102. Crone C, Krarup C. Diagnosis of acute neuropathies. J Neurol. 2007;254:1151–69.

    Google Scholar 

  103. Fokke C, Van Den Berg B, Drenthen J, Walgaard C, Van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137(1):33–43.

    Google Scholar 

  104. Rauschka H, Jellinger K, Lassmann H, Braier F, Schmidbauer M. Guillain-Barré syndrome with marked pleocytosis or a significant proportion of polymorphonuclear granulocytes in the cerebrospinal fluid: neuropathological investigation of five cases and review of differential diagnoses. Europ J Neurol. 2003;10:479–86.

    Google Scholar 

  105. Albers JW, Kelly JJ. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve. 1989;12:435–51.

    Google Scholar 

  106. Bromberg MB, Albers JW. Patterns of sensory nerve conduction abnormalities in demyelinating and axonal peripheral nerve disorders. Muscle Nerve. 1993;16(3):262–6.

    Google Scholar 

  107. Derksen A, Ritter C, Athar P, Kieseier BC, Mancias P, Hartung HP, et al. Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics. Muscle Nerve. 2014;50(5):780–4.

    Google Scholar 

  108. Brown WF, Feasby TE. Conduction block and denervation in Guillain-Barré polyneuropathy. Brain. 1984;107(1):219–39.

    Google Scholar 

  109. Jamal GA, Ballantyne JP. The localization of the lesion in patients with acute ophthalmoplegia, ataxia and areflexia (miller fisher syndrome): A serial multimodal neurophysiological study. Brain. 1988;111(1):95–114.

    Google Scholar 

  110. Scelsa SN, Herskovitz S. Miller Fisher syndrome: axonal, demyelinating or both? Electromyogr Clin Neurophysiol. 2000;40(8):497–502.

    Google Scholar 

  111. Hughes RAC, Bouche P, Cornblath DR, Evers E, Hadden RD, Hahn AF, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripheral Nerv Syst. 2005;10:326–32.

    Google Scholar 

  112. Uncini A, Manzoli C, Notturno F, Capasso M. Pitfalls in electrodiagnosis of Guillain-Barré syndrome subtypes. J Neurol Neurosurg Psychiatry. 2010;81(10):1157–63.

    Google Scholar 

  113. Uncini A, Ippoliti L, Shahrizaila N, Sekiguchi Y, Kuwabara S. Optimizing the electrodiagnostic accuracy in Guillain-Barré syndrome subtypes: criteria sets and sparse linear discriminant analysis. Clin Neurophysiol. 2017;128(7):1176–83.

    Google Scholar 

  114. Hadden RDM, Cornblath DR, Hughes RAC, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Ann Neurol. 1998;44(5):780–8.

    Google Scholar 

  115. Iwata F, Utsumi Y. MR imaging in Guillain-Barre syndrome. Pediatr Radiol. 1997;27(1):36–8.

    Google Scholar 

  116. Telleman JA, Grimm A, Goedee S, Visser LH, Zaidman CM. Nerve ultrasound in polyneuropathies. Muscle Nerve. 2018;57(5):716–28.

    Google Scholar 

  117. Grimm A, Décard BF, Axer H. Ultrasonography of the peripheral nervous system in the early stage of Guillain-Barré syndrome. J Peripher Nerv Syst. 2014;19(3):234–41.

    Google Scholar 

  118. Razali SNO, Arumugam T, Yuki N, Rozalli FI, Goh KJ, Shahrizaila N. Serial peripheral nerve ultrasound in Guillain-Barré syndrome. Clin Neurophysiol. 2016;127(2):1652–6.

    Google Scholar 

  119. French Cooperative Group. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Ann Neurol. 1987;22(6):753–61.

    Google Scholar 

  120. Brettle RP, Gross M, Legg NJ, Lockwood M, Pallis C. Treatment of acute polyneuropathy by plasma exchange. Lancet. 1978;312:1100.

    Google Scholar 

  121. Färkkilä M, Kinnunen E, Haapanen E, Iivanainen M. Guillain-Barré syndrome: quantitative measurement of plasma exchange therapy. Neurology. 1987;37(5):837–40.

    Google Scholar 

  122. Greenwood RJ, Hughes RAC, Bowden AN, Gordon NS, Millac P, Davis JN, et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. J Clin Apher. 1985;2(4):877–9.

    Google Scholar 

  123. Osterman PO, Lundemo G, Pirskanen R, Fagius J, Pihlstedt P, Sidén Å, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1984;324(8415):1296–9.

    Google Scholar 

  124. Plasmapheresis and acute Guillain-Barré syndrome. Neurology. 1985;35(8):1096–104.

    Google Scholar 

  125. Raphaël JC, Chevret S, Chastang C, Jars-Guincestre MC. Appropriate number of plasma exchanges in Guillain-Barre syndrome. Ann Neurol. 1997;41(3):298–306.

    Google Scholar 

  126. Van Der Meché FGA. The Guillain-Barre syndrome: Plasma exchange or immunoglobulins intravenously. J Neurol Neurosurg Psychiatry. 1994;57(SUPPL):293–5.

    Google Scholar 

  127. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology. 1996;46(1):100–3.

    Google Scholar 

  128. Hughes RAC. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet. 1997;349(9047):225–30.

    Google Scholar 

  129. Gürses N, Uysal S, Çetinkaya F, Işek I, Kalayci AG. Intravenous immunoglobulin treatment in children with guillain-barre syndrome. Scand J Infect Dis. 1995;27(3):241–3.

    Google Scholar 

  130. Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics. 2005;116(1):2004–1324.

    Google Scholar 

  131. Verboon C, Van Den Berg B, Cornblath DR, Venema E, Gorson KC, Lunn MP, et al. Original research: second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. J Neurol Neurosurg Psychiatry. 2020;91(2):113–21.

    Google Scholar 

  132. Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, Cornblath DR, van Doorn PA, et al. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): protocol for a double-blind randomized, placebo-controlled clinical trial. J Peripher Nerv Syst. 2018;23(4):210–5.

    Google Scholar 

  133. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North America. 2008;28:803–19.

    Google Scholar 

  134. Kleyweg RP, Van Der Meche FGA. Treatment related fluctuations in Guillain-Barre syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry. 1991;54(11):957–60.

    Google Scholar 

  135. Ropper AH, Albers JW, Addison R. Limited relapse in Guillain-Barré syndrome after plasma exchange. Arch Neurol. 1988;45(3):314–5.

    Google Scholar 

  136. Visser LH, Van Der Meché FGA, Meulstee J, Van Doorn PA. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 1998;64(2):242–4.

    Google Scholar 

  137. Ruts L, Van Koningsveld R, Van Doorn PA. Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations. Neurology. 2005;65(1):1680–6.

    Google Scholar 

  138. Halstead SK, Zitman FMP, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. 2008;131(5):1197–208.

    Google Scholar 

  139. Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, et al. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 2018;17(6):519–29.

    Google Scholar 

  140. McGonigal R, Cunningham ME, Yao D, Barrie JA, Sankaranarayanan S, Fewou SN, et al. C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy. Acta Neuropathol Commun. 2016;4:1–16.

    Google Scholar 

  141. Lansita JA, Mease KM, Qiu H, Yednock T, Sankaranarayanan S, Kramer S. Nonclinical development of ANX005: a humanized Anti-C1q Antibody for treatment of autoimmune and neurodegenerative diseases. Int J Toxicol. 2017;36(6):449–62.

    Google Scholar 

  142. A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) – Full Text View – ClinicalTrials.gov [Internet]. [cited 2020 Oct 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT04035135?cond=guillain+barre+syndrome&draw=2.

  143. Ostronoff F, Perales MA, Stubblefield MD, Hsu KC. Rituximab-responsive Guillain-Barré syndrome following allogeneic hematopoietic SCT. Bone Marrow Transplant. 2008;42(1):71–2.

    Google Scholar 

  144. Marino D, Farina P, Jirillo A, De Franchis G, Simonetto M, Aversa SML. Neurological syndrome after R-CHOP chemotherapy for a non-Hodgkin lymphoma: What is the diagnosis? Int J Hematol. 2011;94(5):461–2.

    Google Scholar 

  145. Carmona A, Alonso JD, de las Heras M, Navarrete A. Guillain-Barre syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyond anecdotal evidence? Clin Transl Oncol. 2006;8(10):764–6.

    Google Scholar 

  146. Tzachanis D, Hamdan A, Uhlmann EJ, Joyce RM. Successful treatment of refractory guillain-barré syndrome with alemtuzumab in a patient with chronic lymphocytic leukemia. Acta Haematol. 2014;132(2):240–3.

    Google Scholar 

  147. Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005;23(10):1283–8.

    Google Scholar 

  148. Zhang G, Bogdanova N, Gao T, Sheikh KA. Elimination of activating Fcγ receptors in spontaneous autoimmune peripheral polyneuropathy model protects from neuropathic disease. PLoS One. 2019;14(8):1–13.

    Google Scholar 

  149. Smith B, Kiessling A, Lledo-Garcia R, Dixon KL, Christodoulou L, Catley MC, et al. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs. 2018;10(7):1111–30.

    Google Scholar 

  150. Kiessling P, Lledo-Garcia R, Watanabe S, Langdon G, Tran D, Bari M, et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Transl Med. 2017;9(414):1–12.

    Google Scholar 

  151. A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy – Full Text View – ClinicalTrials.gov [Internet]. [cited 2020 Oct 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT04051944?type=Intr&cond=cidp&draw=2&rank=3.

  152. Washburn N, Schwabb I, Ortiz D, Bhatnagar N, Lansing JC, Medeiros A, et al. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A. 2015;112(11):297–306.

    Google Scholar 

  153. Zhang G, Massaad CA, Gao T, Pillai L, Bogdanova N, Ghauri S, et al. Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury. Exp Neurol. 2016;282:49–55.

    Google Scholar 

  154. Mehta S. Neuromuscular disease causing acute respiratory failure. Respiratory Care. 2006;51(9):1016–21.

    Google Scholar 

  155. Chung HK. Comparison between EGRIS and outcome of Guillain-Barre syndrome: retrospective study in one center (P06.144). Neurology. 2012;78(Meeting Abstracts 1):144.

    Google Scholar 

  156. Nguyen TN, Badjatia N, Malhotra A, Gibbons FK, Qureshi MM, Greenberg SA. Factors predicting extubation success in patients with Guillain- Barré syndrome. Neurocritical Care. 2006;5:230–4.

    Google Scholar 

  157. Dalos NP, Borel C, Hanley DF. Cardiovascular autonomic dysfunction in Guillain-Barré syndrome: therapeutic implications of Swan-Ganz monitoring. Arch Neurol. 1988;45(1):115–7.

    Google Scholar 

  158. Pandey CK, Bose N, Garg G, Singh N, Baronia A, Agarwal A, et al. Gabapentin for the treatment of pain in Guillain-Barré syndrome: a double-blinded, placebo-controlled, crossover study. Anesth Analg. 2002;95(6):1719–23.

    Google Scholar 

  159. Pandey CK, Raza M, Tripathi M, Navkar D V., Kumar A, Singh UK. The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Anesth Analg. 2005;101(1):220–5.

    Google Scholar 

  160. Singh NK, Gupta A. Do corticosteriods influence the disease course or mortality in Guillain – Barre’ Syndrome? J Assoc Physicians India. 1996;44(1):22–4.

    Google Scholar 

  161. Bansal BC, Sood AK, Gupta AK, Yadav P. Role of steroids in the treatment of Guillain Barre syndrome – a controlled trial. Neurol India. 1986;34(5):329–35.

    Google Scholar 

  162. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet. 1993;341(8845):586–90.

    Google Scholar 

  163. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet. 1978;312(8093):750–3.

    Google Scholar 

  164. Kabore R, Magy L, Boukhris S, Mabrouk T, Lacoste M, Vallat JM. Contribution of corticosteroid to the treatment of pain in the acute phase of Guillain-Barré syndrome. Revue Neurologique. 2004;160:821–3.

    Google Scholar 

  165. Kajimoto M, Koga M, Narumi H, Inoue H, Matsushige T, Ohga S. Successful control of radicular pain in a pediatric patient with Guillain-Barré syndrome. Brain Dev. 2015;37(9):897–900.

    Google Scholar 

  166. Garssen MPJ, Bussmann JBJ, Schmitz PIM, Zandbergen A, Welter TG, Merkies ISJ, et al. Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP. Neurology. 2004;63(12):2393–5.

    Google Scholar 

  167. Pitetti KH, Barrett PJ, Abbas D. Endurance exercise training in Guillain-Barre Syndrome. Arch Phys Med Rehabil. 1993;74(7):761–5.

    Google Scholar 

  168. White CM, Hadden RD, Robert-Lewis SF, McCrone PR, Petty JL. Observer blind randomised controlled trial of a tailored home exercise programme versus usual care in people with stable inflammatory immune mediated neuropathy. BMC Neurol. 2015;15(1):1–9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Division of Neuromuscular Medicine, Virginia Commonwealth University, Richmond, VA, USA

    Kelsey Satkowiak & A. Gordon Smith

Authors
  1. Kelsey Satkowiak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Gordon Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Gordon Smith .

Editor information

Editors and Affiliations

  1. The John and Nancy Nelson Professor of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA

    Karen L. Roos

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Satkowiak, K., Smith, A.G. (2021). Guillain-Barré Syndrome. In: Roos, K.L. (eds) Emergency Neurology. Springer, Cham. https://doi.org/10.1007/978-3-030-75778-6_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-75778-6_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-75777-9

  • Online ISBN: 978-3-030-75778-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation